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Levels of biomarkers of exposure to selected harmful and poten-
tially harmful smoke constituents found in cigarette smoke, in
addition to nicotine were measured in 160 smokers randomized
for 5 days to continuing smoking conventional cigarettes (41 par-
ticipants), switching to Tobacco Heating System 2.2 (THS 2.2) (80
participants), or abstaining from smoking (39 participants). The
data reported here are descriptive statistics of the levels of each
biomarker of exposure expressed as concentrations adjusted to
creatinine; at baseline, and at the end of the study, and their
relative change from baseline. Reductions in the levels of bio-
markers of exposure when expressed as quantity excreted, are also
reported. Detailed descriptions of bioanalytical assays used are also
provided. The data presented here are related to the article entitled
“Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day
randomized reduced exposure clinical study in Poland” (Haziza
et al., 2016) [1].
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Dubject area Pharmacology, toxicology, and pharmaceutical science
ore speciﬁc sub-
ject areaTobacco Harm reductionype of data Table, text
ow data was
acquiredLiquid chromatography-tandem mass spectrometry, spectrophotometry, and
gas chromatography–mass spectrometry.ata format Analyzed
xperimental
factorsUrine and blood sampling collected from healthy smokers participating in the
clinical study. This study is disclosed on clinicaltrials.gov (NCT01959932)xperimental
featuresMeasurements of biomarkers of exposure to selected harmful and potentially
harmful constituents found in cigarette smoke and to to nicotine y after
5 days of use of THS 2.2, conventional cigarettes, or smoking abstinence.ata source
locationWarsaw, Polandata accessibility Data are within this article.D
Value of the data
 The product tested in this clinical study, the Tobacco Heating System 2.2 (THS 2.2), was developed
by Philip Morris International (PMI) as a candidate reduced-risk product aiming to provide an
acceptable alternative to CC smoking, replicating the ritual, taste, sensory characteristics, and
nicotine uptake of conventional cigarette smoking.
 The data provide an understanding on how the levels of biomarkers of exposure compare in
between smokers switching to THS 2.2 or smoking conventional cigarettes.
 The data may be of value to the scientiﬁc community because it offers further insights to other
researchers in the context of tobacco harm reduction strategies.1. Data
Table 1 describes the levels of 15 biomarkers of exposure to selected harmful and potentially
harmful smoke constituents, along with the levels of biomarkers of exposure to nicotine, measured at
baseline and after 5 days of the clinical study investigational period. Carboxyhemoglobin was mea-
sured in in blood (expressed as % of saturation of hemoglobin), nicotine and cotinine were measured
in plasma (expressed in ng/mL), while the other biomarkers of exposure were measured in 24-hour
urine (expressed as concentration adjusted to creatinine). Table 2 shows % of change from baseline
within groups for each biomarker of exposure. Inferential analysis testing (ratio THS/CC expressed as
%) using an ANCOVA model with adjustment to baseline values, sex, conventional cigarette con-
sumption reported at screening, and study arms, is presented in Table 3.2. Experimental design, materials and methods
This study was designed as a controlled, randomized, three-arm parallel, single-center study in
conﬁnement [1]. After the screening visit, the study included 1 day for admission, 2 days of baseline
where smokers were smoking their own brand of CC, followed by a 5 day randomized investigational
period distributed as follows: 41 subjects were randomized to continue CC smoking, 39 subjects were
randomized to smoking abstinence, and 80 subjects were randomized to switch from CC to THS 2.2.
At baseline and 5 days of the investigational period, blood and 24-hour urine were collected to
measure 15 biomarkers of exposure to selected HPHCs. In addition, biomarkers of exposure to
nicotine were assessed.
Table 1
Biomarkers of exposure levels during the study.
Biomarker THS CC SA
N¼80 N¼41 N¼39
NEQa (mg/g creat)
Baseline 9.01 (8.09; 10.03) 8.69 (7.51; 10.04) 9.53 (8.44; 10.76)
Day 5 10.60 (9.34; 12.04) 9.76 (8.54; 11.15) 0.14 (0.12; 0.17)
Nicotinea,b (ng/mL)
Baseline 14.16 (12.62;15.89) 14.03 (11.90; 16.53) 14.39 (12.63; 16.40)
Day 5 20.74 (17.46; 24.62) 19.01 (16.52; 21.87) 0.10 (0.09; 0.12)
Cotininea,b (ng/mL)
Baseline 208.54 (188.61; 230.58) 211.26 (183.05; 243.82) 220.60 (202.10, 240.79)
Day 5 239.99 (211.30; 272.58) 219.73 (190.21; 253.83) 2.05 (1.56; 2.67)
Total NNALa (pg/mg creat)
Baseline 111.01 (95.44; 129.13) 105.05 (84.10; 131.21) 119.40 (94.97; 150.10)
Day 5 49.65 (42.47; 58.05) 107.04 (85.90; 133.37) 41.51 (31.76; 54.26)
Total NNNa (pg/mg creat)
Baseline 4.81 (3.99; 5.78) 4.34 (3.56; 5.28) 5.14 (3.93; 6.70)
Day 5 1.55 (1.17; 2.05) 5.99 (4.94; 7.26) 0.16 (0.14; 0.19)
COHba,c(%)
Baseline 4.65 (4.29; 5.04) 4.68 (4.22; 5.18) 4.96 (4.51; 5.46)
Day 5 1.06 (1.03; 1.08) 4.51 (4.05; 5.01) 0.99 (0.95; 1.03)
MHBMAa (pg/mg creat)
Baseline 1888.27 (1542.95; 2310.86) 2317.31 (1861.41; 2884.85) 1699.39 (1200.16; 2406.29)
Day 5 192.93 (174.90; 212.83) 2399.40 (1884.60; 3054.83) 163.17 (138.41; 192.36)
3-HPMAa (ng/mg creat)
Baseline 841.84 (745.88; 950.14) 799.37 (693.71; 921.13) 861.88 (744.98; 997.12)
Day 5 402.26 (366.55; 441.45) 931.01 (825.73; 1049.72) 245.69 (226.15; 266.91)
S-PMAa (pg/mg creat)
Baseline 2394.03 (1982.83; 2890.50) 2765.20 (2227.38; 3432.88) 2153.82 (1595.57; 2907.38)
Day 5 164.45 (144.45; 187.22) 2922.81 (2362.80; 3615.54) 143.70 (122.15; 169.04)
Total 1-OHPa (pg/mg creat)
Baseline 217.69 (197.88; 239.48) 218.41 (196.28; 243.03) 223.95 (198.89; 252.17)
Day 5a 81.22 (74.82; 88.16) 182.85 (161.24; 207.37) 85.13 (75.37; 96.15)
4-ABPa (pg/mg creat)
Baseline 13.25 (11.85; 14.81) 13.11 (11.33; 15.16) 13.53 (11.71; 15.63)
Day 5 1.9 (1.70; 2.12) 12.58 (11.03; 14.34) 1.60 (1.40; 1.83)
1-NAa (pg/mg creat)
Baseline 73.83 (66.48; 81.99) 77.84 (66.32; 91.36) 77.31 (67.76; 88.21)
Day 5 3.30 (2.89; 3.78) 89.37 (77.81; 102.64) 2.56 (2.25; 2.90)
2-NAa (pg/mg creat)
Baseline 24.54 (22.12; 27.22) 24.14 (21.18; 27.51) 24.59 (21.52; 28.10)
Day 5 2.96 (2.67; 3.28) 25.32 (22.27; 28.79) 2.52 (2.23; 2.84)
o-tola (pg/mg creat)
Baseline 135.20 (122.75; 148.90) 131.32 (115.72; 149.01) 132.49 (114.75; 152.97)
Day 5 51.15 (46.10; 56.75) 121.16 (105.07; 139.71) 41.64 (36.74; 47.18)
CEMAa (ng/mg creat)
Baseline 98.03 (85.10; 112.92) 98.46 (83.81; 115.67) 103.51 (89.35; 119.91)
Day 5 13.18 (11.37; 15.27) 99.48 (85.79; 115.35) 12.6 (10.12; 15.70)
HEMAa (pg/mg creat)
Baseline 4161.66 (3409.70; 5079.44) 4718.48 (3582.18; 6215.23) 4114.78 (3127.42; 5413.84)
Day 5 1342.40 (1140.44; 1580.12) 4504.00 (3506.73; 5784.88) 1248.27 (980.62; 1588.98)
3-HMPMAa (ng/mg creat)
Baseline 479.34 (435.40; 527.72) 460.52 (407.39; 520.59) 443.71 (382.03; 515.35)
Day 5 86.65 (80.31; 93.49) 376.78 (329.54; 430.80) 63.25 (57.79; 69.22)
Total-3-OH-B[a]Pa (fg/mg creat)
Baseline 161.17 (142.28; 182.57) 149.47 (128.96; 173.23) 169.58 (147.04; 195.57)
Day 5 37.07 (33.25; 41.32) 130.29 (110.17; 154.07) 33.64 (28.84; 39.24)
Abbreviations: NC¼not calculated. CC¼conventional cigarette group; SA¼smoking abstinence group; THS¼Tobacco Heating
System 2.2 group.
a Geometric means and 95% conﬁdence intervals are provided in the table. All urinary biomarkers of exposure were
expressed as concentrations adjusted to creatinine.
b Weighted average concentration over 24 h (Cavg).
c Measured between 8:00 PM and 10:00 PM.
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Table 2
Biomarker of exposure, % change from baseline.
Biomarker THS CC SA
N¼80 N¼41 N¼39
NEQ (mg/g creat)
Changea 22.95 (13.92; 31.98) 14.78 (7.04; 22.53) 98.25 (98.67; 97.83)
Nicotineb,c(ng/mL)
Changea 35.98 (19.19; 52.77) 19.68 (1.74; 37.62) 99.19 (99.40; 98.98)
Cotinineb,c(ng/mL)
Changea 11.94 (4.05; 19.84) 0.31 (8.24; 7.63) 98.83 (99.10;-98.56)
Total NNAL (pg/mg creat)
Changea -53.98 (56.69; 51.27) 3.85 (2.84; 10.54) 63.95 (66.98; 60.92)
Total NNN (pg/mg creat)
Changea 69.75 (53.26;-82.75)# 29.93 (12.84; 74.96) 97.04 (94.06; 98.46) #
COHbc(%)
Changea 76.20 (78.11; 74.29) 1.16 (8.31; 5.99) 79.24 (81.09; 77.40)
MHBMA (pg/mg creat)
Changea 84.98 (88.32; 81.63) 6.89 (1.37; 15.15) 79.56 (88.33; 70.79)
3-HPMA (ng/mg creat)
Changea -49.68 (54.32; 45.04) 20.28 (10.41; 30.14) 69.45 (73.27; 65.63)
S-PMA (pg/mg creat)
Changea 92.03 (93.20; 90.85) 9.48 (0.48; 19.45) 91.52 (93.72; 89.33)
Total 1-OHP (pg/mg creat)
Changea 60.17 (63.70; -56.65) 13.52 (21.11; 5.92) 59.94 (64.26; 55.62)
4-ABP (pg/mg creat)
Changea 82.12 (85.59; 78.64) 1.66 (8.59; 5.26) 86.99 (88.87; 85.12)
1-NA (pg/mg creat)
Changea 94.16 (-95.49; 92.82) 19.17 (9.08; 29.26) 96.41 (96.89; 95.93)
2-NA (pg/mg creat)
Changea 85.39 (87.95; 82.82) 7.19 (0.41; 13.97) 88.93 (90.38; 87.47)
o-tol (pg/mg creat)
Changea -50.96 (61.87; 40.05) 3.08 (12.17; 6.01) 64.96 (70.90; 59.01)
CEMA (ng/mg creat)
Changea -86.10 (87.04; 85.17) 4.21 (4.18; 12.61) 86.74 (88.30; 85.17)
HEMA (pg/mg creat)
Changea -60.71 (68.31; 53.11) 0.74 (9.86; 11.34) 64.48 (71.29; 57.66)
HMPMA (ng/mg creat)
Changea -80.58 (82.48; 78.68) 14.53 (22.49; 6.57) 84.39 (86.58; 82.20)
Total-3-OH-B[a]P (fg/mg creat)
Changea 71.43 (76.65; 66.21) 8.92 (17.00; 0.84) 77.24 (81.14; 73.34)
Abbreviations: NC¼not calculated. CC¼conventional cigarette use group; SA¼smoking abstinence group; THS¼Tobacco
Heating System 2.2 use group
a Change: Day 5 % change from baseline; arithmetic mean percent change, and 95% conﬁdence interval. Values are derived
from concentratiosn adjusted to creatinoen for urinary biomarkers of exposure.
b derived from the weighted average concentration over 24 h.
c Measured between 8:00 PM and 10:00 PM. # for total NNN, the change from Baseline was calculated form the
median value.
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States. The assays used for bioanalytical analysis and described below were implemented and vali-
dated in accordance with Celerion standard operating procedures which were written to meet the
FDA Guidance to Industry [2].3. Nicotine equivalents in urine
Bioanalytical assays were developed to quantitate nicotine, cotinine, trans-30-hydroxycotinine,
nicotine-N-glucuronide, cotinine-N-glucuronide, and trans-30-hydroxycotinine-O-glucuronide in
Table 3
Urinary biomarkers of exposure expressed as quantity excreted, ratios of THS relative to CC.
Biomarkers Ratioa(% and CI)
THS (N¼81)/ CC (N¼41)
NEQ (mg/g creat) 97.98 (80.98, 118.54)
Total NNAL (pg/mg creat) 42.79 (37.40; 48.95)
Total NNN (pg/mg creat) 23.45 (17.12, 32.12)
MHBMA (pg/mg creat) 8.17 (6.70; 9.96)
3-HPMA (ng/mg creat) 40.49 (35.84; 45.74)
S-PMA (pg/mg creat) 5.87 (5.03; 6.85)
Total 1-OHP (pg/mg creat) 43.43 (37.67; 50.06)
4-ABP (pg/mg creat) 14.55 (12.51; 16.92)
1-NA (pg/mg creat) 3.66 (3.06; 4.37)
2-NA (pg/mg creat) 11.22 (9.75; 12.91)
o-tol (pg/mg creat) 40.38 (34.92, 46.68)
CEMA (ng/mg creat) 12.96 (11.15, 15.06)
HEMA (pg/mg creat) 31.37 (26.51, 37.11)
3- HMPMA (ng/mg creat) 21.85 (18.83; 25.36)
Total 3-OH-B[a]P (fg/mg creat) 26.62 (22.33, 31.74)
a Ratio: Geometric least squares mean ratio (%) and conﬁdence intervals from an ANCOVA model con-
ducted on log-transformed Day 5 values (urinary biomarker of exposure expressed as quantity) with log-
transformed baseline value, study arm, sex and CC consumption reported at screening as ﬁxed effect factors
(THS/CC) on Day 5. Abbreviations: NC¼not calculated. CC¼conventional cigarette group; CI: Conﬁdence
interval; THS¼Tobacco Heating System 2.2 group.
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surable result, two linear ranges were validated to quantitate samples from subjects that receive
different treatments. For subjects that were randomized to smoking cessation a nine point standard
calibrator line was established across the nicotine (10.0–1000 ng/mL), cotinine (10.0–1000 ng/mL),
trans-30-hydroxycotinine (10.0–1000 ng/mL), nicotine-N-glucuronide (10.0–1000 ng/mL), cotinine-N-
glucuronide (20.0–2000 ng/mL), and trans-30-hydroxycotinine-O-glucuronide (50.0–5000 ng/mL)
analytical ranges. For subjects randomized to conventional cigarettes or the test product the linear
ranges of nicotine (50.0–5000 ng/mL), cotinine (50.0–5000 ng/mL), trans-30-hydroxycotinine (50.0–
5000 ng/mL), nicotine-N-glucuronide (50.0–5000 ng/mL), cotinine-N-glucuronide (200–
20,000 ng/mL), and trans-30-hydroxycotinine-O-glucuronide (200–20,000 ng/mL) were validated.
Calibration standards, quality control samples and clinical samples were supplemented with stable
label internal standards (d4-nicotine, d3-cotinine, d3-trans-30-hydroxycotinine, d3-nicotine-N-glucur-
onide, d3-cotinine-N-glucuronide, d3-trans-30-hydroxycotinine-O-glucuronide). The target analytes
were retained through combined liquid-liquid and solid-phase extraction processes. The eluents were
dried under a stream of nitrogen gas. The extracts were reconstituted with deionized water and were
injected onto an LC-MS/MS system for detection. Positive ions were monitored in multiple reaction
monitoring mode.
The validation testing of the lower concentration range included precision and accuracy testing
with 6 replicates of quality control samples prepared at 4 concentrations (nicotine o9.3% C.V., o7.0%
bias; cotinine o8.6% C.V., o10.6% bias; trans-30-hydroxycotinine o11.5% C.V., o9.5% bias; nicotine-
N-glucuronide o9.2% C.V., o11.3% bias; cotinine-N-glucuronide o11.3% C.V., o10.2% bias; trans-30-
hydroxycotinine-O-glucuronide o8.9% C.V., o7.8% bias), recovery (nicotine 90–101%; cotinine 91–
100%; trans-30-hydroxycotinine 49–52%; nicotine-N-glucuronide 47–54%; cotinine-N-glucuronide 46–
51%; trans-30-hydroxycotinine-O-glucuronide 42–49%), multiple-lot quantitation, stock/sub-stock
solution stability at 20 °C in polypropylene containers, long-term clinical sample stability stored at
20 °C (440 days), freeze/thaw stability (6 cycles under white light), short-term stability (54 h under
white light at ambient temperature), and post-preparative stability (180 h). The validation testing of
the higher concentration range included precision and accuracy testing with 6 replicates of quality
control samples prepared at 4 concentrations (nicotine o9.9% C.V., o13.3% bias; cotinine o5.8% C.
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V., o3.8% bias; cotinine-N-glucuronide o9.8% C.V., o11.5% bias; trans-30-hydroxycotinine-O-glu-
curonide o8.3% C.V., o3.0% bias), recovery (nicotine 100–106%; cotinine 109–120%; trans-30-
hydroxycotinine 49–53%; nicotine-N-glucuronide 48–51%; cotinine-N-glucuronide 44–52%; trans-30-
hydroxycotinine-O-glucuronide 39–46%), multiple-lot quantitation, stock/sub-stock solution stability
at 20 °C in polypropylene containers, long-term clinical sample stability stored at 20 °C (476
days), freeze/thaw stability (6 cycles under white light), short-term stability (57 h under white light at
ambient temperature), and post-preparative stability (229 h). All data from the method validations
were reviewed by an independent quality assurance unit as per Celerion standard operating
procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.4. Nicotine, and cotinine in plasma
For the analysis of nicotine, cotinine in human EDTA plasma 3 bioanalytical assays were validated.
A validated lower concentration range assay was utilized for subjects that were randomized to
smoking cessation. A nine point standard calibrator line was established across the nicotine (0.200–
10.0 ng/mL), and cotinine (1.00–100 ng/mL) analytical ranges. Calibration standards, quality control
samples and clinical samples were supplemented with stable label internal standards (d4-nicotine,
d3-cotinine). The target analytes were retained through a 96-well solid-phase extraction process. The
eluent was injected after dilution onto an LC-MS/MS system for detection. Positive ions were mon-
itored in multiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (nicotine o6.2% C.V., o5.5% bias; cotinine o2.2% C.V., o4.2%
bias), recovery (nicotine 94–97%, cotinine 75–83%), multiple-lot quantitation, hemolyzed sample
integrity, turbid sample integrity, aqueous stock/sub-stock solution stability at 20 °C in poly-
propylene, long-term clinical sample stability (nicotine 1041 days, cotinine 739 days), freeze/thaw
stability (6 cycles under white light), short-term stability (27 h under white light at ambient tem-
perature), and post-preparative stability (321 h). All data from the method validation was reviewed by
an independent quality assurance unit as per Celerion standard operating procedures.
Two higher concentration range assays were validated and then utilized for the analysis of clinical
samples from subjects that were randomized to conventional cigarette or test product use. for the
study, a nine point standard calibrator line was established across the nicotine (1.00–50.0 ng/mL), and
cotinine (1.00–100 ng/mL) analytical ranges. Calibration standards, quality control samples and
clinical samples were supplemented with stable label internal standards (d4-nicotine, d3-cotinine).
The target analytes were retained through a 96-well solid-phase extraction process. The eluent was
injected after dilution onto an LC-MS/MS system for detection. Positive ions were monitored in
multiple reaction monitoring mode.
The validation testing for both high range assays included precision and accuracy testing with
6 replicates of quality control samples prepared at 4 concentrations (nicotine o7.4% C.V., o7.0% bias;
cotinine o11.3% C.V., o10.0% bias), recovery (nicotine 72–78%, cotinine 81–86%), multiple-lot
quantitation, hemolyzed sample integrity, turbid sample integrity, aqueous stock/sub-stock solution
stability at 20 °C in polypropylene, long-term clinical sample stability (220 days), freeze/thaw
stability (6 cycles under white light), short-term stability (49 h under white light at ambient tem-
perature), and post-preparative stability (142 h). All data from the method validation was reviewed by
an independent quality assurance unit as per Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 3 concentrations.
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A bioanalytical assay developed to quantitate 3-Hydroxypropyl Mercapturic Acid (3-HPMA),
Hydroxybutyl Mercapturic Acid (HBMA) and Cyanoethylmercapturic Acid (CEMA) in human urine. A
10 point standard calibrator line was established in artiﬁcial urine (CST Technologies) across the 3-
HPMA and HBMA (20.0–5000 ng/mL) and CEMA (0.275–207 ng/mL) analytical ranges. Calibration
standards, quality control samples and clinical samples were supplemented with stable label internal
standards (15N13C3-3-HPMA, 15N13C3-HBMA, and 15N13C3-CEMA). The target analytes were retained
through a 96-well solid-phase extraction process. The eluents were dried under a stream of nitrogen
gas. The xtracts were reconstituted in deionized water and were injected onto an LC-MS/MS system
for detection. Negative ions were monitored in multiple reaction monitoring (MRM) mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 6 concentrations (3-HPMA o10.2% C.V., o6.3% bias; HBMA o7.6 C.V., 13.5%
bias, CEMA o10.0% C.V., o4.4% bias), recovery (3-HPMA 54–64%, HBMA 76–83%, CEMA 82–86%),
multiple-lot quantitation, stock/sub-stock solution stability at 20 °C in polypropylene, long-term
clinical sample stability (273 days at 20 °C), freeze/thaw stability (7 cycles in brown tubes), short-
term stability (43 h in brown tubes at ambient temperature), and post-preparative stability (152 h in a
polypropylene 96 well plate at 5 °C). All data from the method validation was reviewed by an
independent quality assurance unit as per Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 5 concentrations.6. Aromatic amines in urine
A bioanalytical assay developed to quantitate o-toluidine (o-tol), 1-aminonaphthalene (1-NA), 2-
aminonaphthalene (2-NA) and 4-aminobiphenyl (4-ABP) in human urine. An eight point standard
calibrator line was established in artiﬁcial urine (CST Technologies) across the o-toluidine (50.0–
1000 pg/mL), 1-aminonaphthalene and 2-aminonaphthalene (2.50–500 pg/mL), and 4-
aminobiphenyl (1.50–75.0 pg/mL) analytical ranges. Calibration standards, quality control samples
and clinical samples were supplemented with stable label internal standards ([13C6]o-toluidine, [13C4]
2-aminonaphthalene, [13C6]4-aminobiphenyl). The target analytes were retained through a liquid/
liquid extraction process. The extraction solvent was dried under a stream of nitrogen gas. The
extracts were reconstituted in a polar organic solvent and injected onto an LC-MS/MS system for
detection. Positive ions were monitored in multiple reaction monitoring (MRM) mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 5 concentrations (o-toluidine o9.9% C.V., o3.7% bias; 1-NA o11.7% C.V., o3.3%
bias; 2-NA o12.0 C.V., o5.6% bias, 4-ABP o5.2% C.V., o8.1% bias), recovery (o-toluidine 80.0%, 1-NA
53.0–55.0%, 2-NA 81.0–84.0%, 4-ABP 82.0–84.0%), multiple-lot quantitation, stock/sub-stock solution
stability at 20 °C in polypropylene, long-term clinical sample stability (185 days at 20 °C), freeze/
thaw stability (6 cycles at ambient temperature in brown polypropylene tubes), short-term stability
(54 h at ambient temperature), and post-preparative stability (337 h). All data from the method
validation was reviewed by an independent quality assurance unit as per Celerion standard operating
procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.7. MHBMA in urine
A bioanalytical assay was developed to quantitate monohydroxybutenyl mercapturic acid (MHBMA)
in human urine. A ten point standard calibrator line was established in an artiﬁcial urine across the
MHBMA (0.100–20.0 ng/mL) analytical range. Calibration standards, quality control samples and clinical
samples were supplemented with stable label internal standards (15N13C3-3-MHBMA). The target
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of nitrogen gas. The extracts were reconstituted in a polar organic solvent and injected onto an LC-MS/
MS system for detection. Negative ions were monitored in multiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (o14.7% C.V., o6.0% bias), recovery (82–100%), multiple-lot
quantitation, stock/sub-stock solution stability at 20 °C in polypropylene, long-term clinical sample
stability (158 days at 20 °C), freeze/thaw stability (4 cycles in brown tubes), short-term stability
(20 h protected from white light at ambient temperature), and post-preparative stability (112 h). All
data from the method validation was reviewed by an independent quality assurance unit as per
Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.8. S-PMA and S-BMA in urine
A bioanalytical assay was developed to quantitate S-phenyl mercapturic acid (S-PMA) and S-benzyl
mercapturic acid (S-BMA) in human urine. A 10 point standard calibrator line was established in
deionized water across the SPMA (25.0–6250 ng/mL) and S-BMA (100–25,000 pg/mL) analytical
ranges. Calibration standards, quality control samples and clinical samples were supplemented with
stable label internal standards (13C315N-S-phenyl mercapturic acid, and 13C315N-S-benzyl mercapturic
acid). The target analytes were retained through a solid-phase extraction process. The eluents were
dried under a stream of nitrogen gas. The extracts were reconstituted in a polar organic solvent and
injected onto an LC-MS/MS system for detection. Negative ions were monitored in multiple reaction
monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (S-PMA o12.9% C.V., o14.0% bias, S-BMA o6.8% C.V., o8.0%
bias), recovery (S-PMA 65–75%; S-BMA 79–84%), multiple-lot quantitation, stock/sub-stock solution
stability at 20 °C in polypropylene, long-term clinical sample stability (161 days at 20 °C), freeze/
thaw stability (4 cycles at ambient temperatures protected from light), short-term stability (81 hours
at 5 °C protected from light), and post-preparative stability (181 hours). All data from the method
validation was reviewed by an independent quality assurance unit as per Celerion standard operating
procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.9. Total 1-OHP in urine
A bioanalytical assay was developed to quantitate total 1-hydroxypyrene (1-OHP) in human urine.
An eight point standard calibrator line was established in artiﬁcial urine (CST Technologies) across the
1-OHP (10.0–2000 pg/mL) analytical range. Calibration standards, quality control samples and clinical
samples were supplemented with stable label internal standard (13C6-1-OHP). All samples were
treated with beta-glucuronidase to convert the glucuronide metabolites to the aglycone which was
measured. The target analytes were retained through a solid-phase extraction process. The eluents
were dried under a stream of nitrogen gas. The extracts were reconstituted with a polar solvent
mixture and were injected onto an LC-MS/MS system for detection. Positive ions were monitored in
multiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (o11.0% C.V., o13.4% bias), recovery (78.7–86.9%), multiple-lot
quantitation, stock/sub-stock solution stability at 20 °C in polypropylene, long-term clinical sample
stability (237 days), freeze/thaw stability (6 cycles under white light), short-term stability (17 h at
ambient temperature), and post-preparative stability (55 h). All data from the method validation was
reviewed by an independent quality assurance unit as per Celerion standard operating procedures.
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quality controls prepared at 4 concentrations.10. Total NNN and total NNAL in urine
A bioanalytical assay was developed to quantitate NNAL and NNN in human urine. A 9 point
standard calibrator line was established in ultrapure water across the NNAL (5.00–1000 pg/mL) and
NNN (0.200–40.0 pg/mL) analytical ranges. Calibration standards, quality control samples and clinical
samples were supplemented with stable label internal standards (d4-NNAL and d4-NNN). The target
analytes were retained through a solid phase extraction process. The extraction solvent was dried
under a stream of nitrogen gas. The extracts were reconstituted in a polar organic solvent and injected
onto an LC-MS/MS system for detection. Positive ions were monitored in multiple reaction
monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (NNAL o18.2% C.V., o3.0% bias; NNN o24.6% C.V., o3.5%
bias), recovery (NNAL 88.0–85.0%, NNN 64.0–66.0%), multiple-lot quantitation, stock/sub-stock
solution stability at 20 °C in polypropylene, long-term clinical sample stability (807 days at 20 °C;
318 days (LLOQ QC) and 296 days (dilution QC) at 20 °C), freeze/thaw stability (6 cycles at ambient
temperature for NNAL, 6 cycles at ambient temperature for NNN), short-term stability (24 h at
ambient temperature for NNAL, 24 h at ambient temperature for NNN), and post-preparative stability
(126 h for NNAL, 179 h for NNN). All data from the method validation was reviewed by an inde-
pendent quality assurance unit as per Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.11. Total 3-hydroxy benzo[a]pyrene in urine
A bioanalytical assay was developed to quantitate 3-hydroxybenzo[a]pyrene in human urine. An
eight point standard calibrator line was established across the 3-hydroxybenzo[a]pyrene (25.0–
600 fg/mL) analytical range and was validated. Calibration standards, quality control samples and
clinical samples were supplemented with stable label internal standard (13C6-3-hydroxybenzo[a]
pyrene). All samples were treated with β-glucuronidase to convert the glucuronide metabolite to the
aglycone which was measured. The target analyte was retained through a solid-phase extraction
process. The eluents were dried under a stream of nitrogen gas. The extracts were reconstituted with
a polar organic solvent and were injected onto an LC-MS/MS system for detection. Positive ions were
monitored in multiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 5 concentrations (o15.8% C.V., o2.8% bias), recovery (91–104%), multiple-lot
quantitation, stock/sub-stock solution stability at 20 °C in silanized glass containers, long-term
clinical sample stability stored at 20 °C (570 days), freeze/thaw stability (6 cycles under UV-shielded
light), short-term stability (55 hours under UV-shielded at ambient temperature), and post-
preparative stability (156 h). All data from the method validations were reviewed by an indepen-
dent quality assurance unit as per Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.12. Caffeine and paraxanthine in plasma
A bioanalytical assay was developed to quantitate caffeine and paraxanthine in human plasma. A
9 point standard calibrator line was established in human plasma (heparin) across the caffeine and
paraxanthine (20.0–5000 ng/mL) analytical ranges. Calibration standards, quality control samples and
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xanthine). The target analytes were retained through a liquid-liquid extraction process. The extraction
solvent was dried under a stream of nitrogen gas. The extracts were reconstituted in a polar organic
solvent and injected onto an LC-MS/MS system for detection. Positive ions were monitored in mul-
tiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 4 concentrations (caffeine o7.9% C.V., o3.6% bias; paraxanthine o6.5% C.V.,
o0.6% bias), recovery (caffeine 81.0–87.0%, paraxanthine 59.0–63.0%), multiple-lot quantitation,
stock/sub-stock solution stability at 20 °C in polypropylene, long-term clinical sample stability (545
days at 20 °C), freeze/thaw stability (6 cycles at ambient temperature and in an ice water bath),
short-term stability (24 h at ambient temperature and in an ice water bath), and post-preparative
stability (162 h). All data from the method validation was reviewed by an independent quality
assurance unit as per Celerion standard operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.13. HEMA in urine
A bioanalytical assay was developed to quantitate HEMA in human urine. A nine point standard
calibrator line was established in artiﬁcial urine across the HEMA (0.100–20.0 ng/mL) analytical range.
Calibration standards, quality control samples and clinical samples were supplemented with stable
label internal standard (15N13C3-HEMA). The target analyte was retained through a solid phase
extraction process. The extraction solvent was dried under a stream of nitrogen gas. The extracts were
reconstituted in a polar organic solvent and injected onto an LC-MS/MS system for detection. Positive
ions were monitored in multiple reaction monitoring mode.
The validation testing included precision and accuracy testing with 6 replicates of quality control
samples prepared at 3 concentrations (o6.1% C.V., o4.9% bias), recovery (64–79%), multiple-lot
quantitation, stock/sub-stock solution stability at 20 °C in polypropylene, long-term clinical sample
stability (406 days at 20 °C), freeze/thaw stability (6 cycles at ambient temperature), short-term
stability (27 h at ambient temperature), and post-preparative stability (205 h). All data from the
method validation was reviewed by an independent quality assurance unit as per Celerion standard
operating procedures.
The validated assay was successfully employed to measure the clinical samples with duplicate
quality controls prepared at 4 concentrations.Acknowledgements
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